SNY

SanofiC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$62.00

+44.9% vs current

Most likely

Base case

50%

Probability

Target price

$51.64

+20.7% vs current

B-

Bear case

25%

Probability

Target price

$41.31

-3.5% vs current

AI sentiment snapshot

Latest data as of 2025-10-26

AI commentary

Market tone is cautious-to-neutral: investors are awaiting upcoming quarterly results and several pipeline readouts that could be binary drivers [#PR-Q3-2025]. Recent headlines emphasize macro and FX uncertainty for ADRs, tempering conviction despite stable fundamentals [#MACRO].

RankAlpha Sentiment AI - 2025-10-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventQuarterly results (Q3 2025)Medium impact

Q3 earnings and guidance will set near-term revenue/EBIT expectations and can trigger re-rating or volatility in the ADR [#PR-Q3-2025].

-catalystMacro / FX pressure on ADR valuationHigh impact

USD/EUR moves, interest-rate sensitivity, or broad market risk-off may compress ADR multiples and drive short-term downside [#MACRO].

-catalystLate-stage pipeline regulatory/readoutsHigh impact

Positive late-stage clinical readouts or regulatory approvals in immunology/oncology could drive multi-quarter upside if successful [#CL-2025].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-10-26 • Updated nightlySource: Internal modelMethodology